Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials
NCT06548139 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2024-08-12
Summary
To evaluate the antibody neutralization activity and safety of rabies mAb CBB 1 combination vaccine used in healthy people
Conditions
- Rabies Virus Infection
Interventions
- DRUG
-
Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg
Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
- DRUG
-
Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg
Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
- DRUG
-
Rabies Human Immunoglobulin (HRIG)
Active ingredient: Rabid human immunoglobulin
- BIOLOGICAL
-
Lyophilized rabies vaccine for human use (Vero cells)
Active ingredient: inactivated rabies virus fixed poison
Sponsors & Collaborators
-
The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
collaborator UNKNOWN -
Anning City First People's Hospital
collaborator UNKNOWN -
Yunnan Central Hospital
collaborator UNKNOWN -
Beijing Contreke Statistical Technology Co., LTD
collaborator UNKNOWN -
Military Science Zhengyuan (Beijing) Pharmaceutical Research Co., LTD
collaborator UNKNOWN -
Changchun BCHT Biotechnology Co.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-07-31
- Primary Completion
- 2025-05-31
- Completion
- 2025-05-31
Countries
- China
Study Locations
More Related Trials
-
Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults
NCT01228383 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults
NCT02238756 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate GR1801's Efficacy and Safety
NCT05846568 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects
NCT00656097 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial of Freeze-dried Human Rabies Vaccine (Human Diploid Cells)
NCT07028801 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age
NCT02177032 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Trial of Freeze-dried Human Rabies Vaccine (MRC-5 Cells)
NCT06078423 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)
NCT02139657 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells)
NCT04852068 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations
NCT07120464 ·Status: RECRUITING
-
A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 Years
NCT07275645 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Prevention of Rabies With Four Doses of Rabies Vaccine
NCT05545371 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S Administered Intramuscularly and Intradermally
NCT05937113 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried
NCT07021703 ·Status: RECRUITING ·Phase: PHASE1
-
Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects
NCT02040090 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell)
NCT06177249 ·Status: COMPLETED ·Phase: PHASE3
-
Purified Rabies Vaccine for Human Use (Chick-embryo Cell)
NCT00345319 ·Status: COMPLETED ·Phase: PHASE3
-
Vaccine Prevention of Rabies Adopts 4-shot Immunization Method
NCT05549908 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen
NCT01877395 ·Status: COMPLETED ·Phase: PHASE2
-
RNActive® Rabies Vaccine (CV7201) in Healthy Adults
NCT02241135 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects
NCT03264157 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
NCT04062669 ·Status: COMPLETED ·Phase: PHASE1
-
Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine
NCT05547815 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity Assessment of Subjects Receiving Rabies Post-exposure Prophylaxis in Cambodia
NCT05684185 ·Status: COMPLETED
-
Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells)
NCT05969626 ·Status: UNKNOWN ·Phase: PHASE3